Advancements in Induced Pluripotent Stem Cells

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Gene and Cell Therapy".

Deadline for manuscript submissions: 28 February 2025 | Viewed by 636

Special Issue Editor


E-Mail Website
Guest Editor
Head of Translational Research with iPS Cells Group, Research Institute Hospital 12 de Octubre, i+12, Madrid, Spain
Interests: induced pluripotent stem cells; McArdle disease; mitochondrial disorders; modeling disorders; CRISPR/Cas9; drug repurposing studies; tissue engineering
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Since the creation of induced pluripotent stem cells (iPSCs), by the Nobel Prize laureate Dr. Shinya Yamanaka, many laboratories worldwide are working to generate and apply these cells to the investigation of the ethiopathogeny behind diseases and the search for new therapies against them. The aim of this Special Issue is to collect high-quality papers, fully dedicated to iPSCs and their applications, from top experts in this field. We particularly encourage researchers to submit comprehensive review papers and original articles that showcase the latest advancements in this area. By doing so, we aim to create a collection of high-quality papers that explore the potential of iPSCs and shed light on their diverse applications in addressing various challenges in medical research and treatment.

Dr. M. Esther Gallardo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • induced pluripotent stem cells
  • organoids
  • tissue engineering
  • biomaterials
  • reprogramming
  • iPSC-based cell modelling
  • cell therapy
  • microfluidics
  • drug discovery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

14 pages, 2450 KiB  
Review
Therapeutic Potential of Stem Cell-Derived Extracellular Vesicles in Liver Injury
by Jingjing Dong, Ying Luo and Yingtang Gao
Biomedicines 2024, 12(11), 2489; https://doi.org/10.3390/biomedicines12112489 - 30 Oct 2024
Viewed by 209
Abstract
Liver injury caused by various factors significantly impacts human health. Stem cell transplantation has potential for enhancing liver functionality, but safety concerns such as immune rejection, tumorigenesis, and the formation of emboli in the lungs remain. Recent studies have shown that stem cells [...] Read more.
Liver injury caused by various factors significantly impacts human health. Stem cell transplantation has potential for enhancing liver functionality, but safety concerns such as immune rejection, tumorigenesis, and the formation of emboli in the lungs remain. Recent studies have shown that stem cells primarily exert their effects through the secretion of extracellular vesicles (EVs). EVs have been shown to play crucial roles in reducing inflammation, preventing cell death, and promoting liver cell proliferation. Additionally, they can function as carriers to deliver targeted drugs to the liver, thereby exerting specific physiological effects. EVs possess several advantages, including structural stability, low immunogenicity, minimal tumorigenicity targeting capabilities, and convenient collection. Consequently, EVs have garnered significant attention from researchers and are expected to become alternative therapeutic agents to stem cell therapy. This article provides a comprehensive review of the current research progress in the use of stem cell-derived EVs in the treatment of liver injury. Full article
(This article belongs to the Special Issue Advancements in Induced Pluripotent Stem Cells)
Show Figures

Figure 1

Back to TopTop